Contamination of Sulfonamide Antibiotics and Sulfamethazine-Resistant Bacteria in the Downstream and Estuarine Areas of Jiulong River in Southeast China

Total Page:16

File Type:pdf, Size:1020Kb

Contamination of Sulfonamide Antibiotics and Sulfamethazine-Resistant Bacteria in the Downstream and Estuarine Areas of Jiulong River in Southeast China View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Environ Sci Pollut Res (2015) 22:12104–12113 DOI 10.1007/s11356-015-4473-z RESEARCH ARTICLE Contamination of sulfonamide antibiotics and sulfamethazine-resistant bacteria in the downstream and estuarine areas of Jiulong River in Southeast China Danyun Ou1 & Bin Chen1 & Renao Bai 1 & Puqing Song1 & Heshan Lin1 Received: 28 December 2014 /Accepted: 30 March 2015 /Published online: 16 April 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract Surface water samples from downstream and estu- Introduction arine areas of Jiulong River were collected in August 2011 and May 2012 for detecting sulfonamide antibiotic residues The occurrence of antibiotics in aquatic environments is of and isolating sulfamethazine-resistant bacteria. ecotoxicological concern because of potential ecosystem al- Sulfamethazine was detected in all samples in May 2012 at teration. Prolonged exposure to low doses of antibiotics leads an average concentration of 78.3 ng L−1, which was the to selective proliferation of resistant bacteria, which could highest among the nine sulfonamide antibiotics determined. transfer antimicrobial resistance genes to other bacterial spe- Sulfamethazine-resistant bacteria (SRB) were screened using cies (Dantas et al. 2008;LevyandMarshall2004)with antibiotic-containing agar plates. The SRB average abundance difficult-to-predict consequences on human health (Martínez in the samples was 3.69×104 and 2.17×103 CFUs mL−1 in 2008). The potential of these low antibiotic concentrations to August 2011 and May 2012, respectively, and was positively promote antimicrobial resistance has been substantiated by the correlated to sulfamethazine concentration in May 2012. The detection of several antibiotic-resistant bacteria and/or genes 16S rRNA gene sequencing of all the 121 SRB isolates re- in aquaculture sites (Hoa et al. 2011), municipal wastewater vealed high diversity. Furthermore, the SRB isolates exhibited discharges (Schwartz et al. 2003; Volkmann et al. 2004), lake multidrug resistance, with 48.7 % showing resistance to at water (Czekalski et al. 2012), drinking water (Schwartz et al. least three antibiotics. The abundance and persistence of high- 2003), sediment (Pei et al. 2006), and soil environments ly diverse SRB and their multidrug resistance are likely to (Dantas et al. 2008; Hargrave et al. 2008). Aquatic ecosystems demonstrate the transferable pressure from coastal environ- have been proposed as reservoirs of antimicrobial resistance ments on public health. (Biyela et al. 2004), and resistant bacteria in coastal environ- ments can represent a serious environmental issue and a means for the spread and evolution of antibiotic-resistant bac- Keywords Sulfonamides . Sulfamethazine-resistant teria (Young 1993), thus drawing increasing concern in China. bacteria . Bacterial diversity . Drug resistance . Surface water . Sulfonamides are a big family of sulfonamide-related anti- Southeast China biotics commonly used in clinical and veterinary medicine and have drawn increasing attention of researchers in China Responsible editor: Robert Duran and elsewhere (Gutiérrez et al. 2010; Pinna et al. 2012;Zhu et al. 2013). A number of studies have shown that sulfonamide Electronic supplementary material The online version of this article (doi:10.1007/s11356-015-4473-z) contains supplementary material, residues are widespread in the coastal aquatic environment which is available to authorized users. and may pose high ecological risk to estuaries, such as Bohai Bay (Zhang et al. 2013a), Laizhou Bay (Zhang et al. * Bin Chen 2012), Beibu Gulf (Zheng et al. 2012), and so on (Zou et al. [email protected] 2011). In the environment, sulfonamides can bind to dihydropteroate synthase (DHPS) in the bacterium and inhibit 1 Third Institute of Oceanography, State Oceanic Administration, 178 dihydrofolic acid formation which is essential for bacterial Daxue Road, Xiamen 361005, China growth. Sulfonamide resistance in bacteria is mediated by Environ Sci Pollut Res (2015) 22:12104–12113 12105 the horizontal transfer of the foreign dhps gene or a part of it or sulfathiazole, sulfachloropyridazine, sulfadimethoxine, sulfa- by means of plasmids which carry sul-genes encoding alter- monomethoxine, sulfamethoxydiazine, sulfamethazine, sulfa- native drug-resistant variants of the DHPS enzyme (Sköld diazine, sulfisomidine, sulfacetamide, sulfisoxazole, and 2000). Positive relationship between the number of sulfadoxin, were purchased from Sigma-Aldrich Co. (St. sulfonamide-resistant bacteria and the concentrations of sul- Louis, MO, USA). fonamides was examined indicating that sulfonamides could The water samples were filtered through a mixed cellulose induce bacteria to generate corresponding resistance (Na et al. ester filter (GE, Piscataway, NJ, USA), 0.2 g of edetate 13 2014). Sulfonamides could inhibit the bacterial enzyme activ- disodium and 100 ng of recovery indicator C3-caffein were ity and cause a relative community shift towards gram- added to the filtered water samples and the pH was adjusted to negative bacteria and towards an increased proportion of fun- 3.0. The treated water samples were extracted with SPE de- gal biomass in soil (Gutiérrez et al. 2010; Pinna et al. 2012). vices (Sigma-Aldrich Co.) installed with a HLB column Jiulong River is the second largest river in the Fujian (6 mL, 500 mg, Waters, Milford, MA, USA) at a speed of Province, China; this latter province comprising a population <10 mL min−1. The HLB column was pretreated with 6 mL of more than five million people. High concentration of anti- of methanol and 6 mL of acidified purified water (pH=3.0). biotics has been detected in this watershed (Chen et al. 2013; After extraction, the bound component was eluted with 6 mL Zheng et al. 2011). In the present study, we characterized the of methanol and flushed with nitrogen gas, and then 60 % pattern of contamination by measuring the sulfonamide resi- methanol was added to make the volume up to 1 mL and the dues and sulfamethazine-resistant bacteria (SRB) in the down- liquid was filtered through a 0.2-μm filter (Whatman, stream and estuarine areas of Jiulong River during the rainy Piscataway, NJ, USA). The blank (2 L of purified water) and and dry seasons. Furthermore, the diversity and multidrug recovery indicator (dissolved in 100 mL of seawater) were resistance of SRB were also studied. We aimed to draw public also subjected to the same procedure. Qualitative and quanti- attention on the consequence of antibiotics contamination by tative analyses were performed on a Waters Acquity™ Ultra evaluating the impact of sulfonamides residual on aquatic Performance LC (UPLC) (Waters, Milford, MA, USA) and bacterial community based on the occurrence of mass spectrometer Quattro Premier XE MICROMASS sulfonamide-resistant bacteria and their antimicrobial resis- (Waters), with an electrospray tandem mass spectrometer tance. The results presented here are conspicuous since previ- (ESI-MS-MS) using multi-reactive monitoring mode. ous studies addressing impact of sulfonamides on aquatic mi- crobial parameters failed to highlight any significant effect of Enumeration of SRB the sulfonamide on microbial abundance and diversity. The SRB were enumerated by selective cultivation in marine agar 2216E plates (Difco, BD, Franklin Lakes, NJ, USA) Material and methods supplemented with 350 μgmL−1 sulfamethazine. The water samples were serially diluted with axenic seawater and Sample collection 100 μL of each dilution were spread onto each plate. Escherichia coli was spread to agar amended with and without Surface water samples were collected along the downstream sulfamethazine for the validation of the sulfamethazine- and estuarine areas of Jiulong River in August 2011 and supplement agar. All the dilutions were prepared in triplicate May 2012, and the sampling sites are indicated in Fig. 1. and the plates were incubated at 28 °C for 6–7 days. A bacte- For antibiotic analysis, 1 L of each aqueous sample was indi- rial abundance between 30 and 300 CFUs per plate was used vidually collected in 1 N hydrochloric acid pre-treated glass to estimate the abundance of bacteria in the samples, and the bottles. Simultaneously, for SRB enumeration, 0.5 L of the percentage of SRB was calibrated with total bacteria enumer- aqueous sample was individually collected in sterile bags ated on non-selective 2216E agar plates (Gao et al. 2012b). (Nasco, Fort Atkinson, WI, USA). All the samples were put into an ice-packed cooler and transported back to the labora- SRB diversity analysis tory for immediate processing. The SRB colonies were picked up individually and Sulfonamide antibiotics analysis reinoculated into marine 2216E liquid medium and cultured at 28 °C for 1 day. The total DNA was extracted using a The sulfonamide antibiotics in the water samples were ana- bacterial DNA extraction kit (Omega, Norcross, GA, USA) lyzed using ultra-performance liquid chromatography coupled and employed as a template to amplify the 16S rDNA gene with electrospray tandem mass spectrometry (UPLC–MS- with bacterial primers 27f and 1492r (Frank et al. 2008). The MS) (Su et al. 2007). Standard samples of 14 sulfonamides, PCR products were sequenced (Shenggong Ltd., Shanghai, namely, sulfamethoxazole, sulfamethizole, sulfapyridine, China) and sequence information was generated using 12106 Environ Sci Pollut Res (2015) 22:12104–12113 Fig. 1 Sampling
Recommended publications
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Transdermal Drug Delivery Device Including An
    (19) TZZ_ZZ¥¥_T (11) EP 1 807 033 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61F 13/02 (2006.01) A61L 15/16 (2006.01) 20.07.2016 Bulletin 2016/29 (86) International application number: (21) Application number: 05815555.7 PCT/US2005/035806 (22) Date of filing: 07.10.2005 (87) International publication number: WO 2006/044206 (27.04.2006 Gazette 2006/17) (54) TRANSDERMAL DRUG DELIVERY DEVICE INCLUDING AN OCCLUSIVE BACKING VORRICHTUNG ZUR TRANSDERMALEN VERABREICHUNG VON ARZNEIMITTELN EINSCHLIESSLICH EINER VERSTOPFUNGSSICHERUNG DISPOSITIF D’ADMINISTRATION TRANSDERMIQUE DE MEDICAMENTS AVEC COUCHE SUPPORT OCCLUSIVE (84) Designated Contracting States: • MANTELLE, Juan AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Miami, FL 33186 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • NGUYEN, Viet SK TR Miami, FL 33176 (US) (30) Priority: 08.10.2004 US 616861 P (74) Representative: Awapatent AB P.O. Box 5117 (43) Date of publication of application: 200 71 Malmö (SE) 18.07.2007 Bulletin 2007/29 (56) References cited: (73) Proprietor: NOVEN PHARMACEUTICALS, INC. WO-A-02/36103 WO-A-97/23205 Miami, FL 33186 (US) WO-A-2005/046600 WO-A-2006/028863 US-A- 4 994 278 US-A- 4 994 278 (72) Inventors: US-A- 5 246 705 US-A- 5 474 783 • KANIOS, David US-A- 5 474 783 US-A1- 2001 051 180 Miami, FL 33196 (US) US-A1- 2002 128 345 US-A1- 2006 034 905 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Design, Synthesis, Characterization and Computational Docking Studies of Novel Sulfonamide Derivatives
    EXCLI Journal 2018;17:169-180 – ISSN 1611-2156 Received: October 17, 2017, accepted: January 29, 2017, published: February 01, 2018 Original article: DESIGN, SYNTHESIS, CHARACTERIZATION AND COMPUTATIONAL DOCKING STUDIES OF NOVEL SULFONAMIDE DERIVATIVES Hira Saleem1a, Arooma Maryam1a, Saleem Ahmed Bokhari1a, Ayesha Ashiq1, Sadaf Abdul Rauf2, Rana Rehan Khalid1, Fahim Ashraf Qureshi1b, Abdul Rauf Siddiqi1 ⃰ 1 Department of Biosciences, COMSATS Institute of Information Technology, Islamabad, Pakistan 2 Department of Computer Science, Fatima Jinnah Women University, The Mall, Rawalpindi a Equal contributions, co-first authors b Shared correspondence: [email protected] ⃰ corresponding author: Abdul Rauf Siddiqi, Department of Biosciences, COMSATS Institute of Information Technology, Park Road, Islamabad, Pakistan E-mail: [email protected], [email protected] http://dx.doi.org/10.17179/excli2017-886 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/). ABSTRACT This study reports three novel sulfonamide derivatives 4-Chloro-N-[(4-methylphenyl) sulphonyl]-N-propyl ben- zamide (1A), N-(2-hydroxyphenyl)-4-methyl benzene sulfonamide (1B) and 4-methyl-N-(2-nitrophenyl) ben- zene sulfonamide (1C). The compounds were synthesised from starting material 4-methylbenzenesulfonyl chlo- ride and their structure was studied through 1H-NMR and 13C-NMR spectra. Computational docking was per- formed to estimate their binding energy against bacterial p-amino benzoic acid (PABA) receptor, the dihydrop- teroate synthase (DHPS). The derivatives were tested in vitro for their antimicrobial activity against Gram+ and Gram- bacteria including E. coli, B. subtilis, B. licheniformis and B. linen. 1A was found active only against B.
    [Show full text]
  • A Class-Selective Immunoassay for Sulfonamides Residue Detection in Milk Using a Superior Polyclonal Antibody with Broad Specificity and Highly Uniform Affinity
    Article A Class-Selective Immunoassay for Sulfonamides Residue Detection in Milk Using a Superior Polyclonal Antibody with Broad Specificity and Highly Uniform Affinity Chenglong Li 1, Xiangshu Luo 1, Yonghan Li 2, Huijuan Yang 1, Xiao Liang 3, Kai Wen 1, Yanxin Cao 1, Chao Li 1, Weiyu Wang 1, Weimin Shi 1, Suxia Zhang 1, Xuezhi Yu 1,* and Zhanhui Wang 1 1 Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Veterinary Medicine, China Agricultural University, Beijing Key Laboratory of Detection Technology for Animal- Derived Food Safety, Beijing Laboratory of Food Quality and Safety, 100193 Beijing, China; [email protected] (C.L.); [email protected] (X.L.); [email protected] (H.Y.); [email protected] (K.W.); [email protected] (Y.C.); [email protected] (C.L.); [email protected] (W.W.); [email protected] (W.S.); [email protected] (S.Z.); [email protected] (Z.W.) 2 Henan Animal Health Supervision Institute, 450008 Zhengzhou, China; [email protected] 3 College of Veterinary Medicine, Qingdao Agricultural University, 266109 Qingdao, China; [email protected] * Correspondence: [email protected]; Tel.: +86-10-62734565; Fax: +86-10-62731032 Academic Editors: Patricia Regal and Carlos M. Franco Received: 13 December 2018; Accepted: 24 January 2019; Published: 26 January 2019 Abstract: The development of multianalyte immunoassays with an emphasis on food safety has attracted increasing interest, due to its high target throughput, short detection time, reduced sample consumption, and low overall cost. In this study, a superior polyclonal antibody (pAb) against sulfonamides (SAs) was raised by using a bioconjugate of bovine serum albumin with a rationally designed hapten 4-[(4-aminophenyl) sulfonyl-amino]-2-methoxybenzoic acid (SA10-X).
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,357,385 B2 Laronde Et Al
    US00835.7385B2 (12) United States Patent (10) Patent No.: US 8,357,385 B2 LaRonde et al. (45) Date of Patent: *Jan. 22, 2013 (54) COMBINATION THERAPY FOR THE FOREIGN PATENT DOCUMENTS TREATMENT OF BACTERAL INFECTIONS CA 2243 649 8, 1997 CA 2417 389 2, 2002 Inventors: Frank LaRonde, Toronto (CA); Hanje CA 2438 346 3, 2004 (75) CA 2539 868 4/2005 Chen, Toronto (CA); Selva Sinnadurai, CA 2467 321 11, 2005 Scarborough (CA) CA 2611 577 9, 2007 (73) Assignee: Interface Biologics Inc., Toronto (CA) OTHER PUBLICATIONS Bu et al. A Comparison of Topical Chlorhexidine, Ciprofloxacin, and (*) Notice: Subject to any disclaimer, the term of this Fortified Tobramycin/Cefazolin in Rabbit Models of Staphylococcus patent is extended or adjusted under 35 and Pseudomonas Keratitis. Journal of Ocular Pharmacology and U.S.C. 154(b) by 377 days. Therapeutics, 1997 vol. 23, No. 3, pp. 213-220.* Martin-Navarro et al. The potential pathogenicity of chlorhexidine This patent is Subject to a terminal dis sensittive Acanthamoeba strains isolated from contact lens cases claimer. from asymptomatic individuals in Tenerife, Canary Islands, Spain. Journal of Medical Microbiology. 2008. vol. 57, pp. 1399-1404.* (21) Appl. No.: 12/419,733 Craig et al., Modern Pharmacology. 4' Edition: 545-547, 555-557. 567, 569, 583-586, 651-654, and 849-851. (1994). Filed: Apr. 7, 2009 Jones et al., “Bacterial Resistance: A Worldwide Problem.” Diagn. (22) Microbiol. Infect. Dis. 31:379-388 (1998). Murray, "Antibiotic Resistance.” Adv. Intern. Med. 42:339-367 (65) Prior Publication Data (1997). US 201O/OO62974 A1 Mar. 11, 2010 Nakae, “Multiantibiotic Resistance Caused by Active Drug Extru sion in Pseudomonas aeruginosa and Other Gram-Negative Bacte ria.” Microbiologia.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Control of Phytopathogenic Microorganisms with Pseudomonas Sp. and Substances and Compositions Derived Therefrom
    (19) TZZ Z_Z_T (11) EP 2 820 140 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A01N 63/02 (2006.01) A01N 37/06 (2006.01) 10.01.2018 Bulletin 2018/02 A01N 37/36 (2006.01) A01N 43/08 (2006.01) C12P 1/04 (2006.01) (21) Application number: 13754767.5 (86) International application number: (22) Date of filing: 27.02.2013 PCT/US2013/028112 (87) International publication number: WO 2013/130680 (06.09.2013 Gazette 2013/36) (54) CONTROL OF PHYTOPATHOGENIC MICROORGANISMS WITH PSEUDOMONAS SP. AND SUBSTANCES AND COMPOSITIONS DERIVED THEREFROM BEKÄMPFUNG VON PHYTOPATHOGENEN MIKROORGANISMEN MIT PSEUDOMONAS SP. SOWIE DARAUS HERGESTELLTE SUBSTANZEN UND ZUSAMMENSETZUNGEN RÉGULATION DE MICRO-ORGANISMES PHYTOPATHOGÈNES PAR PSEUDOMONAS SP. ET DES SUBSTANCES ET DES COMPOSITIONS OBTENUES À PARTIR DE CELLE-CI (84) Designated Contracting States: • O. COUILLEROT ET AL: "Pseudomonas AL AT BE BG CH CY CZ DE DK EE ES FI FR GB fluorescens and closely-related fluorescent GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO pseudomonads as biocontrol agents of PL PT RO RS SE SI SK SM TR soil-borne phytopathogens", LETTERS IN APPLIED MICROBIOLOGY, vol. 48, no. 5, 1 May (30) Priority: 28.02.2012 US 201261604507 P 2009 (2009-05-01), pages 505-512, XP55202836, 30.07.2012 US 201261670624 P ISSN: 0266-8254, DOI: 10.1111/j.1472-765X.2009.02566.x (43) Date of publication of application: • GUANPENG GAO ET AL: "Effect of Biocontrol 07.01.2015 Bulletin 2015/02 Agent Pseudomonas fluorescens 2P24 on Soil Fungal Community in Cucumber Rhizosphere (73) Proprietor: Marrone Bio Innovations, Inc.
    [Show full text]
  • D 6.1 EMBRIC Showcases
    Grant Agreement Number: 654008 EMBRIC European Marine Biological Research Infrastructure Cluster to promote the Blue Bioeconomy Horizon 2020 – the Framework Programme for Research and Innovation (2014-2020), H2020-INFRADEV-1-2014-1 Start Date of Project: 01.06.2015 Duration: 48 Months Deliverable D6.1 b EMBRIC showcases: prototype pipelines from the microorganism to product discovery (Revised 2019) HORIZON 2020 - INFRADEV Implementation and operation of cross-cutting services and solutions for clusters of ESFRI 1 Grant agreement no.: 654008 Project acronym: EMBRIC Project website: www.embric.eu Project full title: European Marine Biological Research Infrastructure cluster to promote the Bioeconomy (Revised 2019) Project start date: June 2015 (48 months) Submission due date: May 2019 Actual submission date: Apr 2019 Work Package: WP 6 Microbial pipeline from environment to active compounds Lead Beneficiary: CABI [Partner 15] Version: 1.0 Authors: SMITH David [CABI Partner 15] GOSS Rebecca [USTAN 10] OVERMANN Jörg [DSMZ Partner 24] BRÖNSTRUP Mark [HZI Partner 18] PASCUAL Javier [DSMZ Partner 24] BAJERSKI Felizitas [DSMZ Partner 24] HENSLER Michael [HZI Partner 18] WANG Yunpeng [USTAN Partner 10] ABRAHAM Emily [USTAN Partner 10] FIORINI Federica [HZI Partner 18] Project funded by the European Union’s Horizon 2020 research and innovation programme (2015-2019) Dissemination Level PU Public X PP Restricted to other programme participants (including the Commission Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services 2 Abstract Deliverable D6.1b replaces Deliverable 6.1 EMBRIC showcases: prototype pipelines from the microorganism to product discovery with the specific goal to refine technologies used but more specifically deliver results of the microbial discovery pipeline.
    [Show full text]
  • Removal and Degradation Pathways of Sulfamethoxazole Present in Synthetic Municipal Wastewater Via an Anaerobic Membrane Bioreactor
    Removal and Degradation Pathways of Sulfamethoxazole Present in Synthetic Municipal Wastewater via an Anaerobic Membrane Bioreactor Thesis by Claudia Lorena Sanchez Huerta In Partial Fulfillment of the Requirements For the Degree of Master of Science King Abdullah University of Science and Technology Thuwal, Kingdom of Saudi Arabia April, 2016 2 EXAMINATION COMMITTEE APPROVALS FORM The thesis of Claudia Lorena Sanchez Huerta is approved by the examination committee. Committee Chairperson Prof. TorOve Leiknes Committee Co-Chair Prof. Peiying Hong Committee Member Prof. Pascal Saikaly, Dr. Chunhai Wei 3 © 2016 Claudia Lorena Sanchez Huerta All Rights Reserved 4 ABSTRACT Removal and Degradation Pathways of Sulfamethoxazole Present in Synthetic Municipal Wastewater via an Anaerobic Membrane Bioreactor Claudia Lorena Sanchez Huerta The current global water crisis in addition to continues contamination of natural water bodies with harmful organic micropollutants (OMPs) have driven the development of new water treatment technologies that allow the efficient removal of such compounds. Among a long list of OMPs, antibiotics are considered as top priority pollutants to be treated due to their great resistance to biological treatments and their potential to develop bacterial resistance. Different approaches, such as membrane-based and advance oxidation processes have been proposed to alleviate or minimize antibiotics discharge into aquatic environments. However most of these processes are costly and generate either matrices with high concentration of OMPs or intermediate products with potentially greater toxicity or persistence. Therefore, this thesis proposes the study of an anaerobic membrane bioreactor (AnMBR) for the treatment of synthetic municipal wastewater containing sulfamethoxazole (SMX), a world widely used antibiotic. Besides the general evaluation of AnMBR performance in the COD removal and biogas production, this research mainly focuses on the SMX removal and its degradation pathway.
    [Show full text]
  • A002 Methylobacterium Carri Sp. Nov., Isolated from Automotive Air
    A002 Methylobacterium carri sp. nov., Isolated from Automotive Air Conditioning System Jigwan Son and Jong-Ok Ka* Department of Agricultural Biotechnology and Research Institute of Agriculture and Life Sciences, Seoul National University A bacterial strain, designated DB0501T, with Gram-stain-negative, aerobic, motile, and rod-shaped cell, was isolated from an automotive air conditioning system collected in the Republic of Korea. 16S rRNA gene sequence analysis indicated that the strain DB0501T grouped in the genus Methylobacterium and closely related to Methylobacterium platani PMB02T (98.8%), Methylobacterium currus PR1016AT (97.7%), Methylobacterium variabile DSM 16961T (97.7%), Methylobacterium aquaticum DSM 16371T (97.6%), Methylobacterium tarhaniae N4211T (97.4%) and Methylobacterium frigidaeris IER25-16T (97.2%). Genomic relatedness between strain DB0501T and its closest relatives was evaluated using average nucleotide identity, digital DNA-DNA hybridization and average amino acid identity with values of 86.4–90.8%, 39.3 ± 2.6–48.2 ± 5.0% and 87.8–89.5% respectively. The strain grew 15-30°C , pH 5.5-8.0 and in 0–1.0% w/v NaCl. Summed feature 3 (C16:1 7c and/or C16:1 6c) and summed feature 8 (C18:1 ω7c T and/or C18:1 ω6c) were the predominant cellular fatty acids in strain DB0501 . Q-10 was the major ubiquinone. The major polar lipids were phosphatidylethanolamine, phosphatidylglycerol, and phosphatidylcholine. The DNA G+C content of strain DB0501T was 70.8 mol%. Based on phenotypic, genotypic and chemotaxonomic data, strain DB0501T represents a novel species of the genus Methylobacterium, for which the name Methylobacterium carri sp.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Medication List
    MEDICATION LIST Natural oils found in perfumes and colognes which contain furocoumarins, compounds from natural products such as plants and fruits, can sensitize the skin to sunlight. Food and fruit that contain photosensitizing agents: celery, carrots, lime, coriander, parsley, fennel, dill buttercup, mustard, and figs. Some known photosensitizing medications are listed below by name: Acetohexamide (Dymelor) Gold Salts Sandalwood oil (perfume) Acridine preparations (slight) Grass (meadow) Silver salts Agave Lechuguilla Griseofuivin (Fulvicin) Smartweed (tea) (amaryllis) Hematoporphyrin Sparine Agrimony Hexachlorophene (rare) Stilbamidine Isethionate 9-Aminoacrdine Hydrochlorothiazide Sulfacetamide Aminobenzoic Acid (Esidrix, HydroDiuril) Sulfadiazine Amitriptyline Imipramine HCL (Tofranil) Sulfadimethoxine (Elavil, etc) Isothipencyl (Theruhistin) Sulfaguanidine Anesthetics (Procaine group) Isothipendly (Theruhistin) Sulfanilamide Angelica L-Tryptophan Sulfamerazine Anthracene Lady=s Thumb (tea) Sulfamethazine Antimalarials Lantinin Sulfapyridine Arsenicals Lavender oil Sulfathiazole Barbiturates Lime oil Sulfonamides Bavachi (corylifolia) Meclothiazide (Enduron) Sulfisomidine (Elkosin) Benzene Mepazine (Pacatal) Sulfonylureas (antidiabetics) Benzopyrine 9-Mercaptopurine Temaril Bergamot (perfume) Methoxsalen (Meloxine, Oxsoralen) Terramycin Bithionol (Actamer, Lorothidol) 5-Methoxypsoralen Tetrachlorsalicylanilide (TCSA) Blankophores (sulfa derivatives) 8-Methoxypsoralen Tetracyclines Bulosemide (Jadit) Monoglycerol Thiazides (Diuril,
    [Show full text]